Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Common Equity (2022 - 2025)

Historic Common Equity for Zentalis Pharmaceuticals (ZNTL) over the last 4 years, with Q3 2025 value amounting to $252.9 million.

  • Zentalis Pharmaceuticals' Common Equity fell 2863.34% to $252.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $252.9 million, marking a year-over-year decrease of 2863.34%. This contributed to the annual value of $337.2 million for FY2024, which is 2290.97% down from last year.
  • Zentalis Pharmaceuticals' Common Equity amounted to $252.9 million in Q3 2025, which was down 2863.34% from $274.5 million recorded in Q2 2025.
  • Over the past 5 years, Zentalis Pharmaceuticals' Common Equity peaked at $523.3 million during Q2 2023, and registered a low of $252.9 million during Q3 2025.
  • Moreover, its 4-year median value for Common Equity was $385.7 million (2023), whereas its average is $389.0 million.
  • As far as peak fluctuations go, Zentalis Pharmaceuticals' Common Equity skyrocketed by 2217.5% in 2023, and later crashed by 3561.45% in 2025.
  • Over the past 4 years, Zentalis Pharmaceuticals' Common Equity (Quarter) stood at $434.0 million in 2022, then rose by 0.78% to $437.4 million in 2023, then decreased by 22.91% to $337.2 million in 2024, then decreased by 25.0% to $252.9 million in 2025.
  • Its last three reported values are $252.9 million in Q3 2025, $274.5 million for Q2 2025, and $295.4 million during Q1 2025.